organization · Reporting owner
EPIQ Capital Group, LLC
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Applied Molecular Transport Inc.
Report date December 27, 2023 · Filed December 29, 2023
Jointly reported with Boeding Chad, EPQ LLC AMT PS, EPQ LLC, AMTB PS, EPQ LLC, AMTC PS
Section 16 reporting ended · disclosed 2023-12-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 0 |
Last balance in matching sequence
After 2023-12-27 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2023-12-27 · Other · Disposed 2,149,292 · Balance 6,188,226 F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F2: EPQ LLC, AMT PS is the direct owner of these shares. F6: Upon consummation of the Merger, EPQ LLC, AMT PS received Transaction Consideration of 286,071 shares of Cyclo common stock. F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Row 2 · 2023-12-27 · Other · Disposed 3,394,948 · Balance 2,793,278 F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F3: EPQ LLC, AMTB PS is the direct owner of these shares. F7: Upon consummation of the Merger, EPQ LLC, AMTB PS received Transaction Consideration of 451,868 shares of Cyclo common stock. F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Row 3 · 2023-12-27 · Other · Disposed 2,500,000 · Balance 293,278 F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F4: EPQ LLC, AMTC PS is the direct owner of these shares. F8: Upon consummation of the Merger, EPQ LLC, AMTC PS received Transaction Consideration of 332,750 shares of Cyclo common stock. F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. Row 4 · 2023-12-27 · Other · Disposed 293,278 · Balance 0 F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger. F5: Chad Boeding is the owner of these shares through a trust that he controls. F9: Upon consummation of the Merger, Chad Boeding received Transaction Consideration of 39,036 shares of Cyclo common stock. F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 27, 2023, Applied Molecular Transport Inc. ("AMTI") completed the previously announced strategic combination contemplated by that certain Agreement and Plan of Merger, dated as of September 21, 2023, by and among Cyclo Therapeutics, Inc. ("Cyclo"), Cameo Merger Sub, Inc., a wholly owned subsidiary of Cyclo ("Merger Sub"), and AMTI, providing for the merger of Merger Sub with and into AMTI, with AMTI surviving the merger as a wholly-owned subsidiary of Cyclo (the "Merger"). At the Merger closing, each share of common stock of AMTI reported as disposed of on this Form 4 was automatically converted into the right to receive 0.1331 shares of common stock of Cyclo (the "Transaction Consideration"). Refer to the AMTI Form 8-K filing with the Securities and Exchange Commission dated December 27, 2023 for additional information concerning the Merger.
F2: EPQ LLC, AMT PS is the direct owner of these shares.
F3: EPQ LLC, AMTB PS is the direct owner of these shares.
F4: EPQ LLC, AMTC PS is the direct owner of these shares.
F5: Chad Boeding is the owner of these shares through a trust that he controls.
F6: Upon consummation of the Merger, EPQ LLC, AMT PS received Transaction Consideration of 286,071 shares of Cyclo common stock.
F7: Upon consummation of the Merger, EPQ LLC, AMTB PS received Transaction Consideration of 451,868 shares of Cyclo common stock.
F8: Upon consummation of the Merger, EPQ LLC, AMTC PS received Transaction Consideration of 332,750 shares of Cyclo common stock.
F9: Upon consummation of the Merger, Chad Boeding received Transaction Consideration of 39,036 shares of Cyclo common stock.
F10: EPIQ Capital Group, LLC ("EPIQ") is the managing member of EPQ LLC, AMT PS, EPQ LLC, AMTB PS, and EPQ LLC, AMTC PS (the "EPQ Funds"). Chad Boeding is the Manager of EPIQ.
Lucira Health, Inc.
Report date December 14, 2022 · Filed December 16, 2022
Jointly reported with EPQ LLC, LTEST PS, EPQ LLC, LFLU PS, EPQ LLC, LCOVD PS, EPQ LLC, LCOVD SAFE PS, Boeding Chad
Section 16 reporting ended · disclosed 2022-12-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,694,761 |
Reported balance
After 2022-12-14 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2022-12-14 · Other · Disposed 3,461,764 · Balance 9,694,761 F1: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F2: LTEST is the direct beneficial owner of these shares. |
| Common StockSEC Table I · non-derivative | Direct | 5,940,677 |
Reported balance
After 2022-12-14 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2022-12-14 · Other · Disposed 3,754,084 · Balance 5,940,677 F3: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F4: LFLU is the direct beneficial owner of these shares. |
| Common StockSEC Table I · non-derivative | Direct | 767,651 |
Reported balance
After 2022-12-14 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2022-12-14 · Other · Disposed 5,173,026 · Balance 767,651 F5: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F6: LCOVD is the direct beneficial owner of these shares. |
| Common StockSEC Table I · non-derivative | Direct | 32,176 |
Reported balance
After 2022-12-14 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2022-12-14 · Other · Disposed 735,475 · Balance 32,176 F7: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F8: SAFE is the direct beneficial owner of these shares. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 288,918 |
Reported balance
After 2022-12-14 transaction · row 5
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 5 · 2022-12-14 · Other · Acquired 256,742 · Balance 288,918 F1: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F9: The shares are held directly by Chad Boeding (2,941), a trust of which Mr. Boeding is the trustee and beneficial owner (161,949 shares), and a limited liability company of which Mr. Boeding is the managing member (91,852 shares). |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 1,014,593 |
Reported balance
After 2022-12-14 transaction · row 6
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 6 · 2022-12-14 · Other · Acquired 725,675 · Balance 1,014,593 F1: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). F3: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F5: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F7: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act. F10: The shares are held by entities under control of EPIQ Capital Group, LLC ("EPIQ"). None of the reporting persons has any pecuniary interest in these shares. F11: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. EPIQ, LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: On December 14, 2022, EPQ LLC, LTEST PS ("LTEST") distributed, for no consideration, in the aggregate 3,461,764 shares of the Issuer's Common Stock (the "LTEST Shares") to its members, representing each such member's pro rata interest in such LTEST Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended (the "Exchange Act").
F2: LTEST is the direct beneficial owner of these shares.
F3: On December 14, 2022, EPQ LLC, LFLU PS ("LFLU") distributed, for no consideration, in the aggregate 3,754,084 shares of the Issuer's Common Stock (the "LFLU Shares") to its members, representing each such member's pro rata interest in such LFLU Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act.
F4: LFLU is the direct beneficial owner of these shares.
F5: On December 14, 2022, EPQ LLC, LCOVD PS ("LCOVD") distributed, for no consideration, in the aggregate 5,5173,026 shares of the Issuer's Common Stock (the "LCOVD Shares") to its members, representing each such member's pro rata interest in such LCOVD Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act.
F6: LCOVD is the direct beneficial owner of these shares.
F7: On December 14, 2022, EPQ LLC, LCOVD SAFE PS ("SAFE") distributed, for no consideration, in the aggregate 735,475 shares of the Issuer's Common Stock (the "SAFE Shares") to its members, representing each such member's pro rata interest in such SAFE Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Exchange Act.
F8: SAFE is the direct beneficial owner of these shares.
F9: The shares are held directly by Chad Boeding (2,941), a trust of which Mr. Boeding is the trustee and beneficial owner (161,949 shares), and a limited liability company of which Mr. Boeding is the managing member (91,852 shares).
F10: The shares are held by entities under control of EPIQ Capital Group, LLC ("EPIQ"). None of the reporting persons has any pecuniary interest in these shares.
F11: The reporting persons are EPIQ, Chad Boeding, LFLU, LCOVD, SAFE, and LTEST. EPIQ is the managing member of and LFLU, LCOVD, SAFE, and LTEST. Mr. Boeding is the CEO and Manager of EPIQ. EPIQ is filing this Form 4 on behalf of the reporting persons jointly, but not as a group. EPIQ, LFLU, LCOVD, SAFE, LTEST and Mr. Boeding each disclaims beneficial ownership of the securities reported herein for purposes of Section 16 of the Exchange Act except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Quince Therapeutics, Inc.
Report date December 31, 2020 · Filed February 01, 2021
Jointly reported with Boeding Chad
Section 16 reporting ended · disclosed 2021-02-01. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 10, 2019 Filed Jun 14, 2019 12:48 UTC | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 4,350 | $26.41 | $114,883.50 |
DisclosureSEC source: 0001779453-19-000002 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member 10% owner Boeding Chad · CIK 0001779451 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,822,546 F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 3 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: Beneficially owned directly by Mr. Boeding. Read SEC document |
| May 10, 2019 Filed Nov 29, 2019 12:52 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 80 | $27.05 | $2,164.00 |
DisclosureSEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 3 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as custodian for minor child Disclosed balance after: 2,839,810 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 10, 2019 Filed Nov 29, 2019 12:52 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 4,170 | $27.58 | $115,008.60 |
DisclosureSEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 2 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Mr. Boeding as Trustee of Boeding Family Trust Disclosed balance after: 2,839,730 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Read SEC document |
| May 10, 2019 Filed Nov 29, 2019 12:52 UTC Amendment | Quince Therapeutics, Inc. CRTX · Entity 7403 | PurchaseCommon Stock | 4,350 | $26.41 | $114,883.50 |
DisclosureSEC source: 0001779453-19-000005 · primary_doc.xml · nonDerivative · entry 1 EPIQ Capital Group, LLC · CIK 0001779453 · IA/Managing Member of 10% owne Boeding Chad · CIK 0001779451 · Managing Member of Managing Me Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,835,560 F3 · balance_after: Subsequent to an amended Form 3 filed 11/29/2019, the reporting persons are hereby amending Form 4 filed 6/14/2019 to amend the reported amount of securities beneficially owned for each transaction reported in Table 1. F1 · ownership.direct: The reporting persons are EPIQ Capital Group, LLC ("EPIQ") and Chad Boeding. EPIQ is the investment adviser and managing member of EPQ LLC, CTYM PS ("CTYM") and CTEPQ Partners LLC ("CTEPQ"). Together CTYM and CTEPQ beneficially own +10% of the common stock of the issuer. Mr. Boeding is the Managing Member of EPIQ. EPIQ is filing this Form 4 on behalf of itself and Mr. Boeding jointly, but not as a group, and each reporting person expressly disclaims membership in a group, within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. F2 · ownership.direct: Beneficially owned directly by Mr. Boeding. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.